Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the EU / 2025-520466-22-00
Authorised, recruiting Phase III

Randomised, Open-label, Phase III Study of AZD5335 Versus Mirvetuximab Soravtansine in FRα-high and AZD5335 Versus Investigator’s Choice Chemotherapy in FRα-low Expressing High-grade Platinum-resistant Epithelial Ovarian Cancer Patients (TREVI-OC-01)

2025-520466-22-00 · tracked via the Priya Life Science EU tracker
Sponsor
AstraZeneca AB
Sponsor type
Pharmaceutical company
Therapeutic area
Pathological Conditions, Signs and Symptoms
Decision date
27/03/2026
Enrollment target
309
Sites
Ireland, Greece, Czechia, France, Sweden, Belgium, Denmark, Spain, Italy, Germany

Condition studied

Advanced Platinum-resistant Epithelial Ovarian Cancer

Investigational medicinal product(s)

PACLITAXELDOXORUBICIN HYDROCHLORIDELIPOSOMALAZD5335TOPOTECANMIRVETUXIMAB SORAVTANSINE

Eligibility

Age group
18-64 years, 65+ years
Sex
Female

Primary endpoint

Progression free Survival (PFS): PFS is defined as the time from randomization to radiographic progression as assessed by the Investigator per RECIST v1.1, or death due to any cause.

Endpoint detail

Overall survival (OS): OS is defined as the time from randomisation until the date of death due to any cause.

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-520466-22-00 on CTIS ↗ ← All trials in the EU